Curcumin composition based on two-phase solubilizing system and preparation method of curcumin composition

Abstract

The invention belongs to the technical field of medicines, and relates to a curcumin composition based on a two-phase solubilizing system and a preparation method of the curcumin composition. According to the curcumin composition and the preparation method thereof, polyacrylic resin and cyclodextrin are combined for application, the curcumin composition is prepared through cyclodextrin inclusion and solid dispersion fusion technologies, curcumin exists in the pharmaceutical composition in an amorphous form, and good stability is achieved; compared with a curcumin raw material medicine, the prepared curcumin medicine composition has obviously superior dissolution rate in an environment with the pH value of 1.2; under the condition that the pH is 1.2 and the feeding amount of the same curcumin content, the dissolution rate of the curcumin pharmaceutical composition reaches 100%, and the curcumin raw material medicine is almost insoluble. Meanwhile, compared with a curcumin solid dispersion and a curcumin inclusion compound, the curcumin pharmaceutical composition has the advantage that the dissolution rate of curcumin is remarkably increased.

Description

Technical Field

[0001] The present invention belongs to the field of pharmaceutical technology, and relates to a curcumin composition based on a biphasic solubilization system and a preparation method thereof, in particular to a curcumin composition based on a biphasic solubilization system integrating solid dispersion technology and cyclodextrin inclusion technology and a preparation method thereof. Background Art

[0002] Curcumin is a polyphenolic compound extracted from Curcuma longa L., a plant of the Zingiberaceae family. Due to its bright orange-yellow appearance and antioxidant ability superior to that of α-tocopherol, curcumin is often used as a dye and cooking spice in many countries. A large number of cell experiments and animal experiments have shown that curcumin has a variety of biological activities, including anti-inflammatory, anti-tumor, antioxidant, and antibacterial; however, due to its poor water solubility and rapid degradation at physiological pH, its bioavailability is low and its pharmacokinetics are poor; these characteristics lead to poor actual efficacy of curcumin and limit its clinical application.

[0003] Cyclodextrin inclusion has great research value and excellent application prospects in improving the solubility of insoluble drugs. It is a process in which cyclodextrin (a cyclic oligosaccharide composed of multiple glucose units) and guest molecules spontaneously combine through intermolecular forces (such as van der Waals forces, hydrogen bonds, hydrophobic interactions, etc.) under appropriate conditions to form a host-guest inclusion complex. This inclusion technology can effectively improve the stability and solubility of curcumin, and cyclodextrin is a naturally occurring cyclic oligosaccharide with good biocompatibility and biodegradability. Amorphous solid dispersion (ASD) is also a composition method commonly used to improve the dissolution rate of poorly soluble drugs, in which drug molecules are uniformly dispersed in an amorphous solid solution or suspension formed by excipients. The advantage of ASD is that the kinetic solubility of the drug is higher than that of the crystalline form, and it is possible to form a supersaturated solution during dissolution, thereby improving solubility.

[0004] Research shows that there are obvious limitations in preparing curcumin inclusion complexes using a single cyclodextrin technology, mainly manifested as insufficient inclusion and poor stability, resulting in poor improvement of the drug dissolution rate. For example, for the curcumin inclusion complex prepared using hydroxypropyl-β-cyclodextrin, in a dissolution medium of 900 mL at pH 1.2, when an amount equivalent to 35 mg of curcumin raw material drug is added, the dissolution rate is only 3%. Although there are literature reports that using excipients such as cellulose acetate, Eudragit RL, and glycyrrhizic acid to prepare curcumin solid dispersions can improve the dissolution rate, these studies generally have problems such as low drug dosage (the drug dosage is equivalent to 12 mg of curcumin raw material drug) and dependence on the addition of surfactants (such as Tween 80, Tween 20, etc.) in the dissolution medium, resulting in still limited improvement in the actual dissolution rate of curcumin. In summary, there are obvious deficiencies in improving the dissolution rate of curcumin by single technical means, and it is difficult to meet the actual application requirements.

[0005] Therefore, there is a need for a new curcumin composition and its preparation method to improve the actual dissolution rate of curcumin. SUMMARY OF THE INVENTION

[0006] In view of the technical problems existing in the above-mentioned prior art, the present invention provides a curcumin composition based on a biphasic solubilization system and its preparation method. The present invention innovatively combines acrylic resin (Eudragit ® EPO) with hydroxypropyl-β-cyclodextrin / sulfobutyl-β-cyclodextrin for the first time. Through the organic combination of cyclodextrin inclusion technology and solid dispersion technology, a new type of curcumin composition has been successfully developed. In this system, the introduction of Eudragit ® EPO significantly enhances the stability of the curcumin-hydroxypropyl-β-cyclodextrin / sulfobutyl-β-cyclodextrin system, while the addition of hydroxypropyl-β-cyclodextrin / sulfobutyl-β-cyclodextrin further optimizes the dissolution performance of the curcumin-Eudragit ® EPO system. This combined effect not only overcomes the problem of limited dissolution rate improvement caused by insufficient inclusion and poor stability in traditional cyclodextrin inclusion technology, but also significantly enhances the effect of solid dispersion technology in improving drug dissolution performance, thus achieving a significant increase in the dissolution rate of curcumin. This technology provides an efficient and feasible new strategy for the development of curcumin preparations.

[0007] To achieve the above-mentioned invention objectives, the present invention provides the following technical solutions.

[0008] A curcumin composition based on a biphasic solubilization system, comprising curcumin and a carrier material; the carrier material is acrylic resin and cyclodextrin.

[0009] Further, the acrylic resin is Eudragit® EPO or polyacrylic resin IV.

[0010] Further, the cyclodextrin is hydroxypropyl-β-cyclodextrin (HP-β-CD) or sulfobutyl-β-cyclodextrin (SBE-β-CD).

[0011] Further, the mass ratio of curcumin to the carrier material is 1:5 to 1:9.

[0012] Further, the mass ratio of acrylic resin to cyclodextrin is 2:1 to 8:1.

[0013] A preparation method of a curcumin composition based on a biphasic solubilization system, comprising the following steps: Step 1, accurately weigh cyclodextrin and add it to absolute ethanol, stir at room temperature to dissolve it, and obtain Solution 1; Step 2: Weigh an appropriate amount of curcumin and acrylic resin precisely, and dissolve them ultrasonically in absolute ethanol to obtain Solution 2; Step 3: Drop Solution 2 into Solution 1 drop by drop, and stir until it becomes clear to obtain Solution 3; Step 4: After removing ethanol from Solution 3, place it in a vacuum drying oven at 40°C - 60°C and dry for 12 h - 36 h to obtain a dried substance. Crush it and pass through a No. 5 sieve to obtain the final curcumin composition.

[0014] Furthermore, curcumin exists in an amorphous form.

[0015] Furthermore, the curcumin composition can be used in the fields of preparing drugs, functional foods, etc.

[0016] Compared with the prior art, the beneficial effects of the present invention are as follows.

[0017] 1. The present invention provides a curcumin composition prepared by a technology combining cyclodextrin inclusion and solid dispersion. The preparation method has a simple process, good reproducibility, and low production cost, and can effectively improve the dissolution rate of curcumin.

[0018] 2. Most of the existing curcumin solid dispersions are prepared with a single auxiliary material, such as cellulose acetate, Eudragit RL, glycyrrhizic acid, etc. Although they can improve the dissolution rate of curcumin, the improvement is very limited; the present invention combines solid dispersion technology and cyclodextrin inclusion technology, which can further improve the dissolution rate of curcumin.

[0019] 3. In the dissolution media of some previous curcumin solid dispersions, surfactants such as Tween 20 and Tween 80 are added to improve the dissolution rate of curcumin solid dispersions. This is not only the role of the auxiliary material but also includes solubilization; in addition, the dosage of curcumin in the dissolution test is generally small, about 12 mg; therefore, the actual improvement in the dissolution rate of curcumin is very limited. The dissolution medium of the present invention is 900 ml of pH 1.2 HCl solution, and the dosage is 35 mg. The improvement in the dissolution rate is the synergistic result of combining two technologies and two auxiliary materials, which is an effect that cannot be achieved by any single technology.

[0020] 4. The curcumin composition prepared by combining the existing solid dispersion technology and cyclodextrin inclusion technology is the combination of PVP and β-CD. The result of the dissolution rate determination (dissolution medium: 900 ml of 0.1 N HCl, dosage: 5 mg) is 45%; while the result of the dissolution rate determination of the present invention (dissolution medium: 900 ml of pH 1.2 HCl, dosage: 35 mg) is 100%. Compared with it, the dissolution rate has a significant improvement. Description of the Drawings

[0021] Figure 1Dissolution curves of curcumin bulk drug and curcumin compositions of Examples 1-4 in a medium with pH = 1.2.

[0022] Figure 2 Dissolution curves of curcumin compositions of Example 1 and Comparative Examples 1-4 in a medium with pH = 1.2.

[0023] Figure 3 Scanning electron micrographs of curcumin bulk drug and curcumin composition of Example 1 (A, curcumin bulk drug; B, curcumin composition of Example 1).

[0024] Figure 4 Polarizing microscope images of curcumin bulk drug and curcumin composition of Example 1 (A, curcumin bulk drug; B, curcumin composition of Example 1).

[0025] Figure 5 Differential scanning calorimetry thermograms of curcumin bulk drug and curcumin composition of Example 1 (a, curcumin bulk drug; b, physical mixture of the same ratio in Example 4; c, curcumin composition of Example 1).

[0026] Figure 6 X-ray diffraction patterns of curcumin bulk drug and curcumin composition of Example 1 (a, curcumin bulk drug; b, physical mixture of the same ratio in Example 1; c, curcumin composition of Example 1).

[0027] Figure 7 Curcumin bulk drug, Eudragit ® Molecular docking diagrams among curcumin bulk drug, Eudragit ® EPO, and HP-β-CD (A, results of docking between curcumin bulk drug and HP-β-CD; B, results of docking between curcumin bulk drug and Eudragit ® EPO; C, results of docking between Eudragit ® EPO and HP-β-CD; D, results of docking between curcumin bulk drug and Eudragit

[0028] Figure 8 Curcumin bulk drug, Eudragit ® EPO, HP-β-CD, infrared spectra of physical mixture of the same ratio in Example 1 and curcumin composition of Example 1 (a, curcumin bulk drug; b, Eudragit ® EPO; c, HP-β-CD; d, physical mixture of the same ratio in Example 1; e, curcumin composition of Example 1). Detailed implementation manners

[0029] To facilitate the understanding of the present invention, the technical solutions of the present invention will be comprehensively described below in conjunction with the accompanying drawings and specific embodiments. However, the following described embodiments are only a part of the embodiments of the present invention, rather than all the embodiments, and are only used to illustrate the present invention, and should not be regarded as limiting the scope of the present invention. All other embodiments obtained by those of ordinary skill in the art based on the embodiments of the present invention without creative efforts belong to the scope of protection of the present invention.

[0030] A curcumin composition based on a biphasic solubilization system, comprising curcumin and a carrier material; the carrier material is acrylic resin and cyclodextrin.

[0031] Further, the acrylic resin is Eudragit® EPO or polyacrylic resin IV.

[0032] Further, the cyclodextrin is hydroxypropyl-β-cyclodextrin (HP-β-CD) or sulfobutyl-β-cyclodextrin (SBE-β-CD).

[0033] Further, the mass ratio of curcumin to the carrier material is 1:5 to 1:9.

[0034] Further, the mass ratio of the acrylic resin to the cyclodextrin is 2:1 to 8:1.

[0035] A preparation method of a curcumin composition based on a biphasic solubilization system, comprising the following steps: Step 1: Weigh accurately cyclodextrin and add it to absolute ethanol, stir at room temperature to dissolve it to obtain Solution 1; Step 2: Weigh accurately an appropriate amount of curcumin and acrylic resin, and ultrasonically dissolve them in absolute ethanol to obtain Solution 2; Step 3: Dropwise add Solution 2 to Solution 1, stir until it becomes clear to obtain Solution 3; Step 4: After removing ethanol from Solution 3, place it in a vacuum drying oven at 40°C - 60°C and dry for 12 h - 36 h to obtain a dried substance, pulverize it, and sieve it through a No. 5 sieve to obtain the final curcumin composition.

[0036] Further, curcumin exists in an amorphous form.

[0037] Further, the curcumin composition can be used in the fields of preparing drugs, functional foods, etc.

[0038] Example 1.

[0039] Preparation of the curcumin composition: Weigh accurately 400 mg of HP-β-CD and stir it to dissolve in absolute ethanol at room temperature to obtain Solution 1; Weigh accurately 200 mg of curcumin and Eudragit ®1.0 g of EPO was dissolved in absolute ethanol by ultrasound to obtain Solution 2; Solution 2 was added dropwise to Solution 1, and stirred until clear to obtain Solution 3; after removing the ethanol from Solution 3, it was dried in a vacuum drying oven at 40 °C for 24 h, pulverized, and passed through a No. 5 sieve to obtain the curcumin composition.

[0040] Dissolution test of the drug: According to the Chinese Pharmacopoeia (2020 Edition), the dissolution test was carried out on a ZRS-8GD dissolution system (Tianjin Tianda Tianfa Technology Co., Ltd., Tianjin, China) using the paddle method. Three samples equivalent to 35 mg of curcumin were weighed and added to 900 mL of dissolution medium with pH 1.2, at 37 ± 0.5 °C and 100 rpm. 5 mL of samples were collected at 5, 10, 15, 30, 60, 90, and 120 min and filtered through a 0.45 μm filter membrane. 5 mL of fresh dissolution medium with pH 1.2 was added. The filtrate was analyzed using a UV1600 ultraviolet spectrophotometer (Shanghai Mepuda Instrument Co., Ltd.) at a wavelength of 427 nm. The results are as Figure 1 , at 15 min of this composition, the dissolution rate of curcumin was 100%, showing excellent dissolution performance.

[0041] Example 2.

[0042] Preparation of curcumin composition: 400 mg of SBE-β-CD was accurately weighed and dissolved in absolute ethanol by stirring at room temperature to obtain Solution 1; 200 mg of curcumin and Eudragit ® 1.0 g of EPO was dissolved in absolute ethanol by ultrasound to obtain Solution 2; Solution 2 was added dropwise to Solution 1, and stirred until clear to obtain Solution 3; after removing the ethanol from Solution 3, it was dried in a vacuum drying oven at 40 °C for 24 h, pulverized, and passed through a No. 5 sieve to obtain the curcumin composition.

[0043] Dissolution test of the drug: Three samples equivalent to 35 mg of curcumin were weighed and added to 900 mL of dissolution medium with pH 1.2, and the powder dissolution experiment was carried out according to the method of Example 1. The results are shown in Figure 1 , at 30 min of this composition, the dissolution rate of curcumin was 96%, showing good dissolution performance.

[0044] Example 3.

[0045] Preparation of curcumin composition: 200 mg of HP-β-CD was accurately weighed and dissolved in absolute ethanol by stirring at room temperature to obtain Solution 1; 200 mg of curcumin and Eudragit ®1.2 g of EPO was ultrasonically dissolved in absolute ethanol to obtain Solution 2; Solution 2 was added dropwise to Solution 1, and the mixture was stirred until it became clear to obtain Solution 3; after removing the ethanol from Solution 3, it was dried in a vacuum drying oven at 40 °C for 24 h, pulverized, and passed through a No. 5 sieve to obtain the curcumin composition.

[0046] Dissolution test of the drug: Weigh 3 samples equivalent to 35 mg of curcumin and add them to 900 mL of dissolution medium with pH 1.2 respectively, and perform the powder dissolution experiment according to the method of Example 1. The results are shown in Figure 1 , when it was 30 min for this composition, the dissolution rate of curcumin was 94%, showing good dissolution performance.

[0047] Example 4.

[0048] Preparation of curcumin composition: Accurately weigh 200 mg of SBE-β-CD and stir and dissolve it in absolute ethanol at room temperature to obtain Solution 1; accurately weigh 200 mg of curcumin, Eudragit ® 1.2 g of EPO was ultrasonically dissolved in absolute ethanol to obtain Solution 2; Solution 2 was added dropwise to Solution 1, and the mixture was stirred until it became clear to obtain Solution 3; after removing the ethanol from Solution 3, it was dried in a vacuum drying oven at 40 °C for 24 h, pulverized, and passed through a No. 5 sieve to obtain the curcumin composition.

[0049] Dissolution test of the drug: Weigh 3 samples equivalent to 35 mg of curcumin and add them to 900 mL of dissolution medium with pH 1.2 respectively, and perform the powder dissolution experiment according to the method of Example 1. The results are shown in Figure 1 , when it was 30 min for this composition, the dissolution rate of curcumin was 94%, showing good dissolution performance.

[0050] Comparative Example 1.

[0051] Preparation of curcumin composition: Accurately weigh 200 mg of curcumin, Eudragit ® 1.4 g of EPO was ultrasonically dissolved in absolute ethanol until it was completely dissolved. After removing the ethanol, it was dried in a vacuum drying oven at 40 °C for 24 h, pulverized, and passed through a No. 5 sieve to obtain the curcumin composition.

[0052] Dissolution test of the drug: Weigh 3 samples equivalent to 35 mg of curcumin and add them to 900 mL of dissolution medium with pH 1.2 respectively, and perform the powder dissolution experiment according to the method of Example 1. The results are shown in Figure 2 , when it was 30 min for this composition, the dissolution rate of curcumin was 83%, showing good dissolution performance, but the dissolution rate was not as good as that of the composition using HP-β-CD and Eudragit ® EPO as an adjuvant.

[0053] Comparative Example 2

[0054] Preparation of curcumin composition: Weigh accurately 200 mg of curcumin and 1.4 g of HP-β-CD, dissolve them by ultrasonic in absolute ethanol until completely dissolved. After removing ethanol, dry in a vacuum drying oven at 40 °C for 24 h, pulverize, and sieve through No. 5 sieve to obtain the curcumin composition.

[0055] Dissolution test of the drug: Weigh 3 samples equivalent to 35 mg of curcumin and add them to 900 mL of dissolution medium with pH 1.2 respectively, and conduct the powder dissolution experiment according to the method of Example 1. The results are shown in Figure 2 , when it is 60 min for this composition, the dissolution rate of curcumin is 3%, and the dissolution rate is poor, indicating that the dissolution rate of the composition prepared by using HP-β-CD alone is relatively low.

[0056] Comparative Example 3

[0057] Preparation of curcumin composition: Weigh accurately 600 mg of HP-β-CD and dissolve it by stirring at room temperature in absolute ethanol to obtain Solution 1; weigh accurately 200 mg of curcumin and ® 800 mg of Eudragit EPO, dissolve them by ultrasonic in absolute ethanol to obtain Solution 2; add Solution 2 dropwise to Solution 1, stir until clear to obtain Solution 3; after removing ethanol from Solution 3, dry in a vacuum drying oven at 40 °C for 24 h, pulverize, and sieve through No. 5 sieve to obtain the curcumin composition.

[0058] Dissolution test of the drug: Weigh 3 samples equivalent to 35 mg of curcumin and add them to 900 mL of dissolution medium with pH 1.2 respectively, and conduct the powder dissolution experiment according to the method of Example 1. The results are shown in Figure 2 , when it is 10 min for this composition, the dissolution rate of curcumin is 36%, and the dissolution rate is poor, indicating that when keeping the drug-excipient ratio constant, excessive increasing of the content of HP-β-CD will reduce the dissolution rate.

[0059] Comparative Example 4

[0060] Preparation of curcumin composition: Weigh accurately 100 mg of HP-β-CD and dissolve it by stirring at room temperature in absolute ethanol to obtain Solution 1; weigh accurately 200 mg of curcumin and ® 1.3 g of Eudragit EPO, dissolve them by ultrasonic in absolute ethanol to obtain Solution 2; add Solution 2 dropwise to Solution 1, stir until clear to obtain Solution 3; after removing ethanol from Solution 3, dry in a vacuum drying oven at 40 °C for 24 h, pulverize, and sieve through No. 5 sieve to obtain the curcumin composition.

[0061] Dissolution test of the drug: Weigh 3 samples equivalent to 35 mg of curcumin and add them to 900 mL of dissolution medium with pH 1.2 respectively, and conduct the powder dissolution experiment according to the method of Example 1. The results are shown in Figure 2 , when it comes to 1 h, the dissolution rate of curcumin in this composition is 65%. Compared with Example 1, the dissolution rate decreases, indicating that when keeping the drug-excipient ratio constant, excessive reduction of the content of HP-β-CD will lead to a decrease in the dissolution rate.

[0062] Detection: 1. The morphology of curcumin raw material and the curcumin composition of Example 1 were analyzed using a scanning electron microscope. The samples were first fixed on a metal plate, and gold sputtering treatment was carried out for 30 seconds at a pressure of 8 - 10 Pa using an ion sputtering instrument, and then photographed. The obtained spectra are shown in Figure 3 . Figure 3 A It can be observed that the curcumin raw material presents a columnar crystal form. Figure 3 Irregular blocks were observed in the composition of B, indicating that the curcumin crystals have disappeared and are dispersed in the carrier material in an amorphous form, and the obtained product is amorphous.

[0063] 2. Observe the curcumin raw material and the curcumin composition of Example 1 under a MSHOT MP41 polarized light microscope. The polarized light microscope analysis is as shown in Figure 4 . It shows that obvious birefringence can be observed in the curcumin raw material, indicating that the drug exists in a crystal state ( Figure 4 A), and no birefringence was observed in the curcumin composition, indicating that curcumin exists in the composition in an amorphous state ( Figure 4 B).

[0064] 3. Weigh about 3 mg of the curcumin composition prepared in Example 1 into an aluminum pan, and use a differential scanning calorimeter to detect the thermal behavior of the sample. The nitrogen gas flow rate is 50 mL / min, the heating rate is 10 °C / min, and the scanning range is 10 °C to 300 °C. Take another 5 mg each of the physical mixture and curcumin raw material with the same proportion as Example 4 and operate in the same way. The obtained spectra are shown in Figure 5 . From Figure 5 a, it can be seen that the curcumin raw material has a strong endothermic peak at 184 °C, which is its melting point. However, there is no such endothermic peak in the curcumin composition, indicating that the curcumin crystals have disappeared and are dispersed in the carrier material in an amorphous form, and the obtained product is amorphous ( Figure 5 c). In the physical mixture with the same proportion as Example 4, the melting point peak of the drug becomes wider, indicating that during the heating process, the drug melted in the carrier material ( Figure 5 b).

[0065] 4. Another appropriate amount of curcumin raw material drug, the physical mixture in the same proportion as that in Example 1 was taken, and its diffraction pattern was measured by powder X-ray diffraction method. The results are shown in Figure 6 . As can be seen from Figure 6 a, within the scanning range, the curcumin raw material drug showed strong crystal diffraction peaks at 2θ of 5 ° ~45 ° . The curcumin composition obtained in Example 1 did not show the strong and sharp diffraction peaks of the curcumin raw material drug, indicating that the product obtained in Example 1 was amorphous ( Figure 6 c). The crystal peaks that appeared in the physical mixture in the same proportion as that in Example 1 basically overlapped with the crystal peaks of the raw material drug ( Figure 6 b).

[0066] 5. The curcumin, Eudragit ® EPO, and HP-β-CD in Example 1 were subjected to molecular docking with the help of AutoDock software, and the docking energy was calculated. Finally, the PyMOL 2.5.2 software was used to visually analyze the structure with lower docking energy and paired sites. Figure 7 A is the docking result of curcumin and HP-β-CD. It can be observed that the carbonyl group and carbon-carbon double bond on one side of curcumin were wrapped in the cavity of HP-β-CD, but the docking binding energy was 18.8 kcal / mol, and this number was greater than 0, indicating that the docking of curcumin and HP-β-CD was not stable. It was possible that part of the curcumin would dock with HP-β-CD in the form of Figure 7 E, thus making the whole system stable. However, Figure 7 the E configuration did not conform to the principle of cyclodextrin inclusion. Therefore, using HP-β-CD alone to prepare the curcumin composition could not effectively improve the dissolution rate of curcumin. Figure 7 B is the docking result of curcumin and Eudragit ® EPO. Curcumin and Eudragit ® EPO were connected by hydrogen bonds to form a stable structure. The docking result of Eudragit® EPO and HP-β-CD is shown in Figure 7 C. Eudragit ® EPO did not enter the cavity of HP-β-CD but was combined in a bond-connected manner. As can be seen from Figure 7 D, the addition of Eudragit ® EPO made the binding of curcumin and HP-β-CD tighter, and the energy also decreased from the previous positive value to a negative value. This phenomenon might be due to the combined use of Eudragit ® EPO and HP-β-CD, which made the binding of curcumin and HP-β-CD in the form of Figure 7 A, rather than Figure 7Combined in the form of E, thus making the system stable. Therefore, the solid dispersion technology and the cyclodextrin inclusion technology act together to make the composition more stable. The binding energies of each molecular docking are shown in Table 1.

[0067] Table 1 Binding energies of molecular docking.

[0068] 6. The FTIR-850 (Tianjin Gangdong Technology Development Co., Ltd.) was used to study the molecular interactions in Example 1. Appropriate amounts of curcumin, excipients, and the physical mixture in the same proportion as in Example 1 were taken and prepared by the KBr tablet pressing method. The test range was from 4000 cm -1 to 400 cm -1 with a resolution of 4 cm -1 , and each sample was scanned 32 times. As can be seen from Figure 8 a, for curcumin, the vibration of the carbonyl group (-C=O) can be observed at 1628 cm -1 , and the vibration of the double bond (-C=C) can be observed at 1602 and 1588 cm -1 ; for Eudragit ® EPO, the characteristic peak of the carbonyl group can be observed at 1731 cm -1 ( Figure 8 b); for HP-β-CD, the deformation vibration of C-H can be observed at 1456 cm -1 ( Figure 8 c); in the physical mixture ( Figure 8 d) and the curcumin composition ( Figure 8 e), the characteristic peak of Eudragit ® EPO was not shifted / disappeared, indicating that the carbonyl group in Eudragit ® EPO did not form a hydrogen bond with the hydroxyl group of curcumin and was not encapsulated in HP-β-CD, and it may be combined with the system through other van der Waals forces, electrostatic interactions, etc. However, in the curcumin composition, the vibration of the carbonyl group (-C=O) of curcumin shifted from 1628 cm -1 to 1626 cm -1 , and the stretching vibration of the double bond (-C=C) at 1602 cm -1 disappeared. In addition, it can also be observed that the C-H deformation vibration in HP-β-CD shifted from 1456 cm -1 to 1459 cm -1 . This phenomenon was not found in the physical mixture, proving the formation of the inclusion complex and indicating that the carbonyl group and double bond of curcumin may enter the pores of HP-β-CD.

[0069] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, rather than limiting the protection scope of the present invention. Any simple modification or equivalent replacement made by those of ordinary skill in the art to the technical solution of the present invention shall not depart from the essence and scope of the technical solution of the present invention.

Claims

1. A curcumin composition based on a two-phase solubilization system, characterized in that: The invention comprises curcumin and a carrier material; the carrier material is acrylic resin and cyclodextrin.

2. The curcumin composition based on the two-phase solubilization system according to claim 1, characterized in that The acrylic resin is Eudragit® EPO or polyacrylic acid resin IV.

3. The curcumin composition based on the two-phase solubilization system according to claim 1, characterized in that, The cyclodextrin is hydroxypropyl-β-cyclodextrin or sulfobutyl-β-cyclodextrin.

4. The curcumin composition based on the two-phase solubilization system according to claim 1, characterized in that, The mass ratio of curcumin to the carrier material is 1:5 to 1:

9.

5. The curcumin composition based on the two-phase solubilization system according to claim 1, characterized in that, The mass ratio of acrylic resin to cyclodextrin is 2:1 to 8:

1.

6. A method for preparing a curcumin composition based on a two-phase solubilization system, characterized in that: The following steps are involved: Step 1, accurately weigh cyclodextrin and add it to anhydrous ethanol, stir at room temperature to dissolve it, and obtain solution 1; Step 2, accurately weighing appropriate amounts of curcumin and acrylic resin, and dissolving them in anhydrous ethanol by ultrasonication to obtain solution 2; Step 3, adding solution 2 dropwise into solution 1, clarifying during stirring, to obtain solution 3; Step 4: After removing ethanol from solution 3, the solution is placed in a vacuum drying oven at 40° C. to 60° C. and dried for 12 h to 36 h to obtain a dry substance, which is crushed and passed through a No. 5 sieve to obtain a final curcumin composition.

7. The method for preparing a curcumin composition based on a two-phase solubilization system according to claim 6, characterized in that: The curcumin exists in an amorphous form.

8. The method for preparing a curcumin composition based on a two-phase solubilization system according to claim 6, characterized in that: The curcumin composition is used in the fields of preparing medicines, functional foods, etc.

Images